ROACTEMRA (tocilizumab), immunosuppressive agent

Insufficient clinical benefit in other clinical situations, particularly in the treatment of recently diagnosed or recurrent giant cell arteritis, in the absence of corticosteroid dependence and/or intolerance.

• Subcutaneous ROACTEMRA has now been granted an MA for the treatment of adults suffering from giant cell arteritis (GCA).

• When combined with decreasing 26-week corticotherapy, its superiority is demonstrated versus placebo in terms of remission at 52 weeks.

• Its tolerance profile is characterised by infectious, haematological, hepatic and gastrointestinal adverse effects.

• ROACTEMRA presents a clinical benefit only in patients requiring cortisone-sparing.